RedNova News - ...Click to read...Researchers at the University of Alabama at Birmingham are getting ready to test the experimental cancer therapy, Reolysin as a viable treatment in treating recurrent malignant gliomas, some of the most aggressive and deadly brain tumors.
The studies are sponsored by Oncolytics Biotech and as described by their lead scientist Dr. Matthew Coffey in published scientific journals, including Science and The EMBO Journal, the reovirus is able to replicate in cancer cells with an activated Ras pathway, without harming healthy cells. The Ras Pathway is instrumental in transferring growth signals to the nucleus of a cell, telling the cell when and how to grow -- much like an "on-off" switch.